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Abstract 
Hemophilia A and B are rare inherited bleeding disorders resulting from deficiency of coagulation factors 
VIII and IX respectively. In the past few decades, the field of hemophilia has witnessed pivotal 
management challenges and therapeutic advances. Routine coagulation and factor assays, while useful 
in the classification of severity and treatment monitoring in hemophilia patients, have been shown to be 
of limited use in managing clinical presentations and outcomes. This prompted the investigation of 
viscoelastic studies in hemophilia care, which have established their utility in various bleeding and 
thrombotic states. In this review, we will discuss and critically assess the current literature highlighting 
the use of viscoelastic studies in various aspects of hemophilia including the determination of clinical 
phenotype, management of patients with inhibitors, perioperative management, and monitoring of 
novel agents.   
Introduction 
Thromboelastography was first described over half a century ago by Hellmut Hartert. 1 Ever since, it has 
evolved from predominantly research use to wide clinical applications. As a global coagulation assay, 
thromboelastography provides a continuous assessment of clot formation and lysis, via the 
measurement of viscoelastic properties of whole blood under the effect of constant rotational force. 2-4 
Two modern technologies have adapted Hartert’s principle; the TEG® device manufactured by 
Haemonetics Corporation (Braintree, MA, USA) and the ROTEM® device distributed by Instrumentation 
Laboratory (Bedford, MA, USA). Both instruments (TEG® 5000 and ROTEM® delta) consist of a sample 
cup, into which a pin is suspended that is connected to a torsion wire. The torsion wire is in turn 
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monitored for movement. Ultimately, a graphical tracing is resulted in real time, depicting clot initiation, 
propagation, stabilization and clot lysis. 2–4 Results obtained with the TEG® technology are often referred 
to as thromboelastography, while results from the ROTEM® based technology are described as 
thromboelastometry. Overall, the parameters generated from both instruments are considered 
comparable albeit not directly interchangeable.  
Thromboelastography can measure the coagulation pattern in the sample either by relying primarily on 
contact activation with the cup (called native TEG®) or as is done more commonly, where coagulation is 
accelerated utilizing intrinsic or extrinsic pathway activators which allows for transportation of the 
specimen to a lab and thereby increase utility and reliability of the assay. Commercial reagents are 
available through the manufacturing companies. For the TEG®, kaolin coated vials are provided for 
intrinsic pathway activation, while for the ROTEM®, the manufacturer provides reagents for both 
intrinsic activation (INTEM [partial thromboplastin phospholipid from rabbit brain]) and extrinsic 
activation (EXTEM [thromboplastin/recombinant tissue factor]). Investigators have utilized recombinant 
human tissue factor (mostly Innovin; Siemens Healthcare Diagnostics, Erlangen, Germany) for extrinsic 
activation with TEG® at different dilutions in an improvised fashion. This has been a source of 
controversy, as tissue factor (TF) mediated extrinsic pathway activation is considered by some to be the 
more physiologic route but its’ use has been complicated by several factors including the significant 
variability among different sources of TF, the lot-to-lot variability of TF given its biologic nature,  the 
need to dilute the TF reagent several logs with the TEG® technology, further increasing the variability, 
and finally the question regarding the need for contact system inhibition using corn trypsin inhibitor 
(CTI) when employing minimal concentrations of TF (<1 pmol), which itself is associated with few 
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limitations including financial cost. 2,5,6 Consequently, the Scientific and Standardization Committee (SSC) 
of ISTH has recommended utilizing intrinsic pathway activation with kaolin (TEG®) or INTEM (ROTEM®) 
for routine clinical use awaiting further validation of extrinsic pathway activators. 7  
As a whole blood assay, viscoelastic testing is believed to account for the integral role of the cellular and 
acellular elements in clot formation, i.e., platelets, red blood cells, leukocytes and enzymatic factors of 
coagulation. The low shear forces utilized in these instruments are comparable to those of the venous 
circulation. 2,3,7 Viscoelastic testing can be performed at the point of care, providing results in real-time. 
As a result, it has become an integral tool in hemostatic monitoring and transfusion management in 
cardiovascular surgery, liver transplant and trauma and critical care surgery, among others. 8–10 Over the 
past two decades, viscoelastic assays have been studied in the diagnosis and management of inherited 
and acquired bleeding disorders, including hemophilia. 2,7  
Hemophilia A and B result from the deficiency of coagulation factors VIII and IX, respectively. Clinical 
severity is divided according to factor level into severe (FVIII <1%), moderate (FVIII 1-5%), and mild (FVIII 
>5%). Patients with severe hemophilia tend to suffer from debilitating spontaneous joint or muscle 
hemorrhages, while patients with mild deficiency are mostly at risk of post traumatic and post-surgical 
bleeding.  
Conventional coagulation and factor assays have been routinely used in the diagnosis and management 
of hemophilia, but have been found to have several limitations. Prothrombin time (PT) and activated 
partial thromboplastin time (aPTT) lack platelets and only reflect the initiation of coagulation. For 
example, the aPTT measures the time to initiation of clot formation where only 5% of total thrombin has 
been generated. Neither assay provides information regarding the rate and strength of clot formation, 
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nor lysis. In addition, both assays can be prolonged by other interfering proteins. Furthermore, It has 
been demonstrated that the aPTT based FVIII:C assay does not necessarily correlate with clinical 
severity. 11,12 Such limitations and the emergent needs in the care of hemophilia patients, such as 
monitoring bypassing agent therapy in inhibitor patients where routine assays cannot be used, have 
triggered the search for new ways to assess the coagulation status in hemophilia patients. Thus, global 
assays including thromboelastography have been studied to complement routine assays in confronting 
challenges in hemophilia care.  
This review summarizes and critically discusses the significance and current use of viscoelastic testing for 
the most relevant aspects of hemophilia care. 
 
Phenotype heterogeneity of hemophilia 
A considerable heterogeneity in clinical phenotype is recognized among patients with hemophilia. An 
estimated 10-15% of patients with severe hemophilia A demonstrate a mild clinical phenotype, and 
conversely, patients with mild hemophilia may exhibit severe hemorrhagic manifestations. 11,12 FVIII:C 
and related aPTT although useful for the classification and management guidance in hemophilia, do not 
consistently correlate with the clinical phenotype. 
Viscoelastic testing has been shown to help differentiate the clinical phenotype in such patients. The 
pioneering work of Sorensen et al. demonstrated variations in whole blood coagulation pattern in 
patients with hemophilia and other rare coagulation disorders utilizing thromboelastometry with 
minimal tissue factor activation. This variation was evident on the routine parameters including clotting 
time (CT) and maximal clot firmness (MCF). 12 Furthermore, inter-individual variation was shown in 
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response to ex vivo addition of rFVIIa, indicating the potential clinical role of thromboelastometry in 
dose titration of rFVIIa. Another report by Chitlur et al. demonstrated that patients with a mild 
phenotype and no target joints had better clot formation and higher thrombin generation (MTG) on 
TEG® 5000 compared to those with a more severe phenotype and presence of target joints. 13  
Figure 1 depicts TEG® tracings of patients with severe hemophilia A and FVIII:C <1%, with clear 
differences in coagulation patterns, with those with milder phenotype showing earlier (shorter R time) 
and better clot formation (steeper angle). Thus, TEG® technology can be considered a valuable method 
for better understanding of hemostasis and bleeding phenotype, and consequently tailoring 
individualized prophylaxis regimens. 
Another aspect of phenotype determination is the differentiation between severe hemophilia patients 
with and without inhibitors, where the factor assay is inadequate for level detection below 1%. Patients 
with severe hemophilia (factor level < 1%) are anticipated to have unmeasurable residual factor activity, 
whereas the presence of neutralizing antibody in inhibitor patients theoretically eliminates any residual 
activity. Salinas et al. demonstrated the ability of kaolin-activated thromboelastography to distinguish 
between severe hemophilia A with and without inhibitors, where non-inhibitor patients were shown to 
have shorter reaction and kinetics time. TF activated TEG® and TGA, both with and without CTI, on the 
other hand were not able to distinguish patients with and without inhibitors, and none of the assays 
correlated with the annualized bleeding rates in these patients. 14 
While such reports have laid the ground work for the wider use of thromboelastography in hemophilia, 
other reports have been contradictory. Tarandovskiy et al. have studied different global assays in 
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hemophilia, and have not found a difference in R time, angle or maximum amplitude when comparing 
TEG® in severe hemophilia A patients with severe and mild phenotypes. 15 It is unclear whether this is 
the result of assay discrepancy, reagent sensitivity or other modifiers of coagulation in the patient 
population. In other studies, TEG® in mild hemophilia A has not been found to be sensitive enough to 
distinguish mild hemophilia A from normal controls and did not correlate with bleeding phenotype. 16,17 
Bowyer et al. also reported the lack of correlation of ROTEM® parameters in 14 patients with mild 
hemophilia A and discrepant one stage and chromogenic FVIII levels. 16 
Monitoring of routine FVIII prophylaxis 
Patient care in hemophilia is becoming increasingly individualized. With the availability of newer factor 
products with half-life extension, prophylaxis regimens are being tailored to allow patients to pursue 
sports and other activities. Given wide inter-patient variability in response to routine FVIII prophylaxis, 
pharmacokinetic (PK) and pharmacodynamic (PD) studies are thought to be essential for formulation of 
individualized treatment plans.  
Thromboelastography can complement conventionally used plasma based FVIII assays. Al Hawaj et al. 
correlated R time on TEG® analyzer tracings with aPTT and FVIII activity during a 48-h period of rFVIII 
prophylaxis in 8 severe hemophilia A patients with various bleeding phenotypes. At 48 hours, 
thromboelastography lost sensitivity similar to the undetectable level of FVIII activity. 18 This implies 
that, having a POC PK result from thromboelastography may allow alterations in the prophylaxis 
regimen to be made in a timelier manner. Anecdotally at our center, visual thromboelastography read-
outs with the time to clot have been found to be a very useful tool, to encourage and ensure patient 
compliance with prophylaxis. TEG® tracings for two patients with severe hemophilia A and variable half-
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life response to FVIII supplementation are shown in Figure 2. Patient (1) demonstrates minimal 
coagulation pattern at 48 hours post FVIII infusion, necessitating a more frequent prophylaxis regimen. 
In contrast to patient (2), where sufficient coagulation is evident at 48 hours post infusion thus requiring 
a less frequent infusion schedule. 
 
Response to bypassing agents 
Bypassing agents, such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex 
concentrate (aPCC), are successful in controlling bleeding episodes in inhibitor patients in approximately 
80-90% of cases. Nevertheless they are not as effective as native FVIII or FIX products 19–21. When using 
bypassing agents, routine assessment of factor levels or aPTT/PT are no longer an option for monitoring 
therapy and other parameters to guide the choice of bypassing agent, optimum dosing and monitoring 
of response to therapy are needed.  
Viscoelastic testing may provide useful information to guide the use of bypassing agents; occasionally 
patients demonstrate clinical responsiveness to either aPCC or rFVIIa, and thromboelastography has 
been used to determine the agent to which the patient shows better response. 22,23 Such information is 
particularly valuable in the setting of uncontrolled bleeding or perioperative planning in patients with 
inhibitors. Young et al. used thromboelastography in the formulation of an effective individualized 
treatment plan in challenging inhibitor patients. TEG® technology was noted to be useful in 
demonstrating response and half- life assessment of rFVIIa and FEIBA® infusions separately or in 
combination leading to improved control of bleeding episodes while decreasing number of infusions and 
hospitalization days. 24 
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Figure 3A is an example of how thromboelastography was used in a patient with severe hemophilia A 
with high-titer inhibitors, who failed immune tolerance induction three times. He was maintained on 
treatment with rFVIIa for management of bleeding with good response, but presented with a hip joint 
bleed not responding to rFVII over several days. Faced with hesitation to use plasma derived aPCC, 
thromboelastography was utilized, which showed superior response to aPCC compared to rFVIIa, and 
was subsequently given for treatment with excellent response. Without the availability of viscoelastic 
testing, treatment is primarily empiric and responsive, based on monitoring of clinical presentation. 
While rFVIIa is conventionally used in repeated doses (90 mcg/kg for 3 doses), the single high dose 
regimen of 270 mcg/kg has been shown to be equally efficacious with potentially faster resolution of 
bleeding, convenience and decreased injection related pain. 25 The single high dosing regimen is used 
more widely in Europe, compared to US or Canada. Recently, Fernandez-Bello et al. evaluated TEG® 
technology and thrombin generation assay (TGA) in the two dosing regimens, demonstrating the 
correlation of thromboelastography and TGA with PK studies. Additionally, the maximum thrombin 
generation (MTG) on the TEG® highlighted the persistent hemostatic state after the 3 doses regimen for 
up to 9 hours. This finding may suggest the benefit of an additional 90 mcg/kg dose of rFVIIa 6-9 hours 
following an initial 270 mcg/kg dose to maintain hemostasis. 26 Studies like this allow us to have 
objective data to assist with the use of bypassing agents. 
 
Perioperative management  
Surgical interventions in hemophilia patients, especially those with inhibitors, require a multidisciplinary 
approach and meticulous planning to achieve successful outcomes. 27 Determining the optimal 
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frequency and dose of factor replacement in the perioperative period is key to favorable outcomes. This 
can be extremely difficult to do using only a FVIII assay as the test result is usually not available in real 
time. In patients with Factor VIII inhibitors, no factor assay can be utilized. Furukawa et al. successfully 
used ROTEM® analysis in a 3-step protocol for preoperative planning for severe hemophilia A patients 
with high titer inhibitor. The 1st step included in vitro studies after spiking blood samples with rFVIIa and 
aPCC, which allowed determining the superior response and optimal dosing. Accordingly, the 2nd step 
involved preoperative evaluation of the in vivo response to the agent and dosing of choice. Lastly, a 3rd 
analysis was performed 30 minutes peri-operatively to confirm adequate hemostasis. 28 Similarly, 
Croteau et al. describe the case of a 5-year old hemophilia A patient with high-titer and refractory 
immune tolerance induction (ITI) undergoing high-risk cardiac surgery. TEG® analysis was used in the 
preoperative setting to effectively assess the potential of various hemostatic agents, including 
recombinant porcine FVIII and aPCC. 29 Thus, these assays can be extremely beneficial and allow the 
hematologist to evaluate both risks and benefits of treatment options. 
Thromboelastography is particularly vital in the setting of emergent surgery in hemophilia patients; as 
perioperative planning is not possible, and rapidly obtained PT and aPTT are limited in the monitoring of 
hemostasis particularly when bypassing agents are used. Pivalizza et al. used both TEG® and ROTEM® 
technologies to monitor hemostasis during an emergent evacuation of spinal hematoma surgery. Larger 
doses of rFVIIa (at 200 and 300 mcg/kg) were used preoperatively and intraoperatively, guided by TEG® 
and ROTEM® parameters. An important point to delineate, is that Pivalizza et al. employed different 
activators in each modality, Kaolin in TEG®5000 analyzers and TF in ROTEM® analyzers, yielding 
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comparable results. This is important to note in the ongoing quest for the optimal activator to be used 
with viscoelastic testing in hemophilia patients. 30 
As higher life expectancy is achieved in patients with hemophilia, age related disorders including 
cardiovascular disease and requirement for cardiothoracic surgery are becoming more prevalent. 31,32 
Cardiac surgery is a major hemostatic challenge as a result of sternotomy, the need of total 
heparinization, extracorporal circulation, mild hypothermia and cardiac arrest. Bedside 
thromboelastography has been found to be a valuable tool during coronary artery bypass grafting 
(CABG) surgery by Misgav et al., where they utilized prolonged R time on the heparinase cup TEG® 
analysis as an indicator of the need for additional FVIII supplementation. Heparinase cup TEG® analysis 
eliminates the heparin effect and is a better reflection of the patient’s underlying hemostatic state, 
which is of particular importance when systemic anticoagulation is required in hemophilia patients. 33 
 
Novel therapeutic approaches 
 
The emergence of novel therapeutic modalities has revolutionized the treatment of hemophilia patients, 
specifically those with inhibitors. Promising treatment approaches include extended half-life FVIII/FIX 
products, monoclonal antibodies targeting tissue factor pathway inhibitor (TFPI), siRNA targeting 
antithrombin, and the bispecific antibody emicizumab (Hemlibra®). 34 These new therapeutic modalities 
will require new testing methodologies to monitor, as routine testing methods like clotting times or 
factor assays cannot be used to measure their response or efficacy. 
Emicizumab is a recombinant, humanized, bispecific monoclonal antibody that bridges activated factor 
IX and factor X to restore the function of deficient activated factor VIII resulting in effective hemostasis. 
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The HAVEN trials have reported ground breaking results, showing a remarkable reduction in bleeding 
rates with emicizumab prophylaxis in children with hemophilia A with and without inhibitor. 35–37 Drug 
levels and novel XIa based assays were used in the clinical trial for PK studies and hemostasis 
monitoring. APTT based FVIII assays are normal at steady state despite breakthrough bleeding episodes, 
raising the question if this is an artificial correction of assays from the monoclonal antibody rather than 
true normalized hemostasis.38,39  
Figure 3B shows data from a patient with high titer inhibitors on weekly emicizumab and in-vitro spiking 
with bypassing agents and recombinant porcine FVIII (rPFVIII). It clearly demonstrates that his baseline 
coagulation does not change with rFVIIa and rPFVIII but greatly enhances with the use of aPCC. This is a 
particularly interesting albeit an isolated finding, as the use of aPCC averaging at 100 U/kg for more than 
1 day during emicizumab prophylaxis was linked to the occurrence of thrombotic microangiopathy and 
thrombotic events in 5 patients in the HAVEN1 trial. 35 We have not observed similar findings in our 
aforementioned patient with high-titer inhibitor in figure 3A, who was initiated on weekly emicizumab 
with dramatic response. When he presented with thrombotic microangiopathy following treatment with 
aPCC for 5 days for ankle bleeding while on emicizumab prophylaxis, thromboelastography parameters 
were not suggestive of an enhanced hemostatic state. Thus, indicating that further studies are necessary 
to validate the sensitivity of viscoelastic studies in the monitoring of patients on innovative therapeutic 
agents.  
 
Acquired hemophilia 
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Acquired inhibitors against FVIII is an autoimmune disorder that affects mostly older individuals and 
young females during pregnancy or the post-partum period. 40,41 Half of the cases are idiopathic and 
bleeding is usually spontaneous and can be life-threatening. Treatment of hemorrhages is done with 
bypassing agents or recombinant porcine FVIII. 42 Figure 4A depicts a patient with an acquired inhibitor 
titer of 55 Bethesda units (BU) and the in-vitro response to bypassing agents and rPFVIII. Figure 4B 
depicts the same patient 3 months later (inhibitor titer of 12 BU) after treatment with 
immunosuppressants and improvement of her baseline curve and bleeding episodes, although the in-
vitro response to hemostatic agents did not change.  
 
Limitations and Future Opportunities 
Despite the promising applications of viscoelastic testing in hemophilia, experience thus far is based on 
small sized studies and case reports while larger randomized studies are lacking. Broader utilization is 
limited by pre-analytical and analytical factors. The blood sample should be obtained via a 21-gauge or 
larger needle and analyzed within 4 hours of collection to minimize platelet activation. The older 
viscoelastic instruments are sensitive to vibration, and manual pipetting is required with the use of TEG® 
5000 while ROTEM® delta utilizes automatic pipetting. Furthermore, the aforementioned controversies 
regarding the choice of the viscoelastic activators (extrinsic vs intrinsic activation), and the source and 
concentration of tissue factor was a major drawback to the use of extrinsic activators with the TEG 5000. 
The newer models, TEG® 6s and the ROTEM® sigma, have integrated cartridges prefilled with reagents 
aiming to improve practicality of use and precision. In light of changes in methodology, studies are 
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necessary to determine if the newer technologies have better reproducibility and sensitivity which were 
issues with the prior models. 
Standardization and quality assurance of viscoelastic testing is challenged by the inter operator and inter 
laboratory variation. Coefficients of variation of 2.6–11.2 % for ROTEM® delta and 7.4–19% for TEG® 
5000 parameters were reported in a study with seven operators. 43 Comparison of inter laboratory 
external quality assurance (EQA) samples have shown inferior precision of 7–49% for TEG® 5000 and 7–
83% for ROTEM® delta. 44 Similar to the standardization of PFA-100, another whole blood assay, this can 
be hopefully overcome by utilizing externally standardized reagents and methods for local quality 
assurance. Additionally, standardization can be further facilitated by the development of easier to use 
technologies, such as the cartridge based TEG® 6s analyzer. This will help reduce variance and allow for 
superior external quality control and inter and intra-laboratory comparability.  
The introduction of new therapies may require new activators or other modifications of currently 
available viscoelastic testing systems. If successfully addressed this may ultimately result in the 
increased utilization of viscoelastic studies as current conventional coagulation testing does not fully 
address the clinical need. 
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